1. Percutaneous cryoablation
- Author
-
D. J. van der Reijd, T. R. Baetens, F. Gomez Munoz, B. M. Aarts, M. J. Lahaye, N. M. Graafland, C. A. R. Lok, A. G. J. Aalbers, N. F. M. Kok, R. G. H. Beets-Tan, M. Maas, E. G. Klompenhouwer, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, School Office GROW, and Faculteit FHML Centraal
- Subjects
OUTCOMES ,RESECTION ,Radiological and Ultrasound Technology ,FEASIBILITY ,Urology ,Gastroenterology ,Abdominal Cavity ,Metastases ,Cryosurgery ,Kidney Neoplasms ,COLORECTAL-CANCER ,Treatment Outcome ,RENAL-CELL CARCINOMA ,Neoplasms ,Abdomen ,Interventional Radiology ,SURVEILLANCE ,Humans ,Radiology, Nuclear Medicine and imaging ,Female ,GUIDED CRYOABLATION ,Tomography, X-Ray Computed ,RECURRENCE ,Retrospective Studies - Abstract
Purpose To assess the primary safety and oncological outcome of percutaneous cryoablation in patients with non-visceral metastases of the abdominal cavity after prior surgery. Methods All patients with non-visceral metastases after prior abdominal surgery, treated with percutaneous cryoablation, and at least one year of follow-up were retrospectively identified. Technical success was achieved if the ice-ball had a minimum margin of 10 mm in three dimensions on the per-procedural CT images. Complications were recorded using the Society of Interventional Radiology (SIR) classification system. Time until disease progression was monitored with follow-up CT and/or MRI. Local control was defined as absence of recurrence at the site of ablation. Results Eleven patients underwent cryoablation for 14 non-visceral metastases (mean diameter 20 ± 9 mm). Primary tumor origin was renal cell (n = 4), colorectal (n = 3), granulosa cell (n = 2), endometrium (n = 1) and appendix (n = 1) carcinoma. Treated metastases were localized retroperitoneal (n = 8), intraperitoneal (n = 2), or in the abdominal wall (n = 4). Technical success was achieved in all procedures. After a median follow-up of 27 months (12–38 months), all patients were alive. Local control was observed in 10/14 non-visceral metastases, and the earliest local progression was detected after ten months. No major adverse events occurred. One patient suffered a minor asymptomatic adverse event. Conclusion This proof-of-concept study suggests that cryoablation can be a minimal invasive treatment option in a selected group of patients with non-visceral metastases in the abdominal cavity after prior surgery. Graphical abstract
- Published
- 2022
- Full Text
- View/download PDF